PDCD1 and non-small cell lung carcinoma: Over the last two years, the U.S. Food and Drug Administration (FDA) has granted approval to the anti–PD-1 inhibitors, nivolumab (OPDIVO) and pembrolizumab (KEYTRUDA) and the anti–PD-L1 inhibitor, atezolizumab (TECENTRIQ) for the treatment of patients with advanced NSCLC with progression during or after first-line therapy [1,2,3].